Prenosis, a biology-based technology company delivering integrated diagnostics and therapeutics, announced today two major milestones: completion of its Series A Financing Round, and a contract from the Biomedical Advanced Research and Development Authority (BARDA), a component of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).

The $20 million financing round was led by PACE Healthcare Capital, with premier co-investors including UC Investments, UCI Health Ventures, the Labcorp Venture Fund, Global Health Investment Corporation (GHIC), Illinois Department of Commerce and Economic Opportunity (DCEO), and Carle Health. This financing will continue to support the commercial delivery of Prenosis' Sepsis ImmunoScore®, the first FDA-authorized AI diagnostic tool for sepsis.

Prenosis is a biology-based technology company redefining the standard of care for critical conditions. They believe healthcare should not follow a one-size-fits-all model. Instead, their mission is to tailor healthcare to each patient's biology through the creation and delivery of integrated diagnostics and therapeutics. Prenosis uses deep data and AI to build tools that augment clinical diagnosis of critical conditions based on each patient's unique biological profile. Unlike other AI-driven diagnostics, they go further by developing therapies that help providers deliver personalized care. Their Immunix™ platform powers the development of a variety of AI-based diagnostics, including Sepsis ImmunoScore®, the first FDA-authorized AI diagnostic tool for sepsis.